首页>投融资
Thryv Therapeutics
未透露
Thryv Therapeutics Inc (formerly LQT Therapeutics Inc), is a biopharmaceutical company discovering and developing therapies for the treatment of all forms of Long QT Syndrome (LQTS).In August 2021, LQT Therapeutics Inc had completed US$19 million Series A financing.In January 2020, the company had raised a upto C$1.8 million in round of funding led by Fonds de solidarite FTQ
基本信息
-
公司全称Thryv Therapeutics Inc
-
类型肿瘤治疗药物开发商
-
产业领域生物/化学技术、化学药
-
公司人数15人以下
-
地址500 Boulevard Cartier Ouest LAVAL QUEBEC H7V 5B7; CA; Telephone: +15145770753;
-
联系电话(514) 577-0753
-
邮箱admin@lqttrx.com
-
成立时间2019-01-01
投融资
-
2023-06-06未透露500万美元Investissement Quebec
-
2021-08-13A轮1900万美元Fonds de Solidarite FTQAlexandria Venture InvestmentsLumira VenturesAmplitude Venture CapitalAmzak Health Investors
-
2020-01-08种子轮1437万美元Fonds de Solidarite FTQ
相关投融资企业
未透露
Thryv Therapeutics Inc (formerly LQT Therapeutics Inc), is a biopharmaceutical company discovering and developing therapies for the treatment of all forms of Long QT Syndrome (LQTS).In August 2021, LQT Therapeutics Inc had completed US$19 million Series A financing.In January 2020, the company had raised a upto C$1.8 million in round of funding led by Fonds de solidarite FTQ
A轮
LQT Therapeutics是一家开发遗传性心脏病精准疗法的生物医药公司，该公司正在开发一种治疗长QT综合征（Long QT Syndrome，LQTS）和其他潜在心律失常患者的精准医学方法。LQTS是一种遗传性疾病，在心跳过程中引起Q波和T波之间的延长，可导致心跳快速、混乱或心律失常。该疾病患者会出现昏厥、癫痫发作、心脏骤停或猝死。LQT Therapeutics正在推进由赛诺菲发现和开发的一系列许可化合物，这些化合物可抑制血清或糖皮质激素调节激酶1（SGK1）。该公司创始人最近进行的研究证实，这种新型激酶是导致包括长QT综合征在内的各种心律失常中钠调节不当的关键因素。进一步的研究还验证了SGK1抑制对前列腺癌和结直肠癌细胞增殖通路的影响。LQT Therapeutics将继续探索，在各种代谢通路上，上调激活SGK1的其他作用。
A轮
Thryv Therapeutics Inc (formerly LQT Therapeutics Inc), is a biopharmaceutical company discovering and developing therapies for the treatment of all forms of Long QT Syndrome (LQTS).In August 2021, LQT Therapeutics Inc had completed US$19 million Series A financing.In January 2020, the company had raised a upto C$1.8 million in round of funding led by Fonds de solidarite FTQ
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息